← ZhuZhou QianJin Pharmaceutical overview

ZhuZhou QianJin Pharmaceutical vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

ZhuZhou QianJin Pharmaceutical Co Ltd (600479.CG)

Q3 2026
▲4

Qianjin Pharmaceutical Profit Jumps 42% on New Drug Approvals and Procurement Wins

  • Four products win national procurement slots through 2029 Four Qianjin products — dydrogesterone, iguratimod, baricitinib and alogliptin tablets — were tentatively selected in China's 12th national drug bulk-buy. That locks in guaranteed sales volume to end-2029, giving the company a steadier, more predictable revenue base and supporting the share price.

    This is the biggest new commercial event, securing multi-year sales volume for four products.

  • Five new drug approvals expand product line Subsidiaries won registration certificates for Baclofen tablets plus minoxidil liniment, ezetimibe tablets, amlodipine benazepril capsules and ursodeoxycholic acid capsules. These add fresh revenue streams, though each is small today — Baclofen's whole China market was only 247 million yuan in 2025.

    New product approvals are the pipeline that feeds future growth, a core reason the stock is being re-rated.

  • First-half profit up 41.6%, fifth straight year of growth H1 revenue rose 5.5% to 1.918 billion yuan while net profit jumped 41.6% to 181 million yuan, with second-quarter revenue up 16.6%. Operating cash flow more than tripled. Profit growing far faster than sales shows better margins and cost control, a strong signal for the shares.

    The interim results are the single clearest evidence of improving profitability and cash generation.

  • Dividend of 1.8 yuan per 10 shares planned Management proposed a cash dividend of 1.8 yuan per 10 shares, about 88.6 million yuan total — roughly half of first-half profit returned to shareholders. A solid payout signals confidence in cash flow and gives income-focused investors a reason to hold the stock.

    The dividend is a concrete capital return that supports valuation and investor confidence.

August 2026
▲4

Qianjin Pharmaceutical Profit Jumps 42% on New Drug Approvals and Procurement Wins

  • Four products win national procurement slots through 2029 Four Qianjin products — dydrogesterone, iguratimod, baricitinib and alogliptin tablets — were tentatively selected in China's 12th national drug bulk-buy. That locks in guaranteed sales volume to end-2029, giving the company a steadier, more predictable revenue base and supporting the share price.

    This is the biggest new commercial event, securing multi-year sales volume for four products.

  • Five new drug approvals expand product line Subsidiaries won registration certificates for Baclofen tablets plus minoxidil liniment, ezetimibe tablets, amlodipine benazepril capsules and ursodeoxycholic acid capsules. These add fresh revenue streams, though each is small today — Baclofen's whole China market was only 247 million yuan in 2025.

    New product approvals are the pipeline that feeds future growth, a core reason the stock is being re-rated.

  • First-half profit up 41.6%, fifth straight year of growth H1 revenue rose 5.5% to 1.918 billion yuan while net profit jumped 41.6% to 181 million yuan, with second-quarter revenue up 16.6%. Operating cash flow more than tripled. Profit growing far faster than sales shows better margins and cost control, a strong signal for the shares.

    The interim results are the single clearest evidence of improving profitability and cash generation.

  • Dividend of 1.8 yuan per 10 shares planned Management proposed a cash dividend of 1.8 yuan per 10 shares, about 88.6 million yuan total — roughly half of first-half profit returned to shareholders. A solid payout signals confidence in cash flow and gives income-focused investors a reason to hold the stock.

    The dividend is a concrete capital return that supports valuation and investor confidence.

Latest
▲4

Qianjin Pharmaceutical Profit Jumps 42% on New Drug Approvals and Procurement Wins

  • Four products win national procurement slots through 2029 Four Qianjin products — dydrogesterone, iguratimod, baricitinib and alogliptin tablets — were tentatively selected in China's 12th national drug bulk-buy. That locks in guaranteed sales volume to end-2029, giving the company a steadier, more predictable revenue base and supporting the share price.

    This is the biggest new commercial event, securing multi-year sales volume for four products.

  • Five new drug approvals expand product line Subsidiaries won registration certificates for Baclofen tablets plus minoxidil liniment, ezetimibe tablets, amlodipine benazepril capsules and ursodeoxycholic acid capsules. These add fresh revenue streams, though each is small today — Baclofen's whole China market was only 247 million yuan in 2025.

    New product approvals are the pipeline that feeds future growth, a core reason the stock is being re-rated.

  • First-half profit up 41.6%, fifth straight year of growth H1 revenue rose 5.5% to 1.918 billion yuan while net profit jumped 41.6% to 181 million yuan, with second-quarter revenue up 16.6%. Operating cash flow more than tripled. Profit growing far faster than sales shows better margins and cost control, a strong signal for the shares.

    The interim results are the single clearest evidence of improving profitability and cash generation.

  • Dividend of 1.8 yuan per 10 shares planned Management proposed a cash dividend of 1.8 yuan per 10 shares, about 88.6 million yuan total — roughly half of first-half profit returned to shareholders. A solid payout signals confidence in cash flow and gives income-focused investors a reason to hold the stock.

    The dividend is a concrete capital return that supports valuation and investor confidence.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

August 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

Latest
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.